The Filing Desk

Voyager Therapeutics vs Wave Life Sciences

Voyager Therapeutics VYGR · Wave Life Sciences WVE · Biotechnology

Wave Life Sciences reported revenue of $43 million in fiscal 2025, about the same as Voyager Therapeutics' $40 million in fiscal 2025. Voyager Therapeutics' revenue fell 49.5% in its latest year, and Wave Life Sciences' fell 60.5%. Voyager Therapeutics had an operating margin of -326.6%, against -504.1% at Wave Life Sciences. Free cash flow was −$135 million at Voyager Therapeutics and −$188 million at Wave Life Sciences.

Side by side

Voyager TherapeuticsWave Life Sciences
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$40M$43M
Revenue growth−49.5%−60.5%
Revenue growth a year, last 5 years−25.1%16.3%
Gross margin——
Operating margin−326.6%−504.1%
Net margin−296.5%−478.3%
Free cash flow−$135M−$188M
Free cash flow margin−334.5%−440.5%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count1.8%22.0%
Last close$1.61$2.72
P/E at the last close——
Insider trades, last 12 monthssold $297,957bought $82.6 million, sold $16.1 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Voyager TherapeuticsWave Life Sciences
Operating margin
Percent of revenue
Voyager TherapeuticsWave Life Sciences
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Voyager TherapeuticsWave Life Sciences

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Voyager Therapeutics and Wave Life Sciences pages.